Dosimetric Evaluation of Permanent Prostate Brachytherapy Using Cs-131 Sources
Authors: Steven Kurtzman, M.D
- Home
- About
- Brachytherapy
Patient Information
Clinician Information
Cesium 131 Products
- Theranostics
- Newsroom
- Investor Center
- Contact us
Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer
Authors
W. James Morris, MD, FRCPC, W. James Morris MD, FRCPC, Scott Tyldesley, MD, FRCPC, ...
- Published in journal:
International Journal of Radiation Oncology Biology and Physics
November 16, 2016
Related posts
Long-Term Quality of Life in Prostate Cancer Patients Treated With Cesium-131
Authors: Glaser SM, Chen KS, Benoit RM, Smith RP, Beriwal S.
Is Cs-131 or I-125 or Pd-103 the “Ideal” Isotope for Prostate Boost Brachytherapy?–A Dosimetric View Point
Authors: R. Yaparpalvi, J. Rossinow, W.A. Cavanagh, W. Choi, L. Minsky, N. Kahan, W. Bodner, M. Garg, S. Kalnicki, C. Guha
Cesium131 Prostate Brachytherapy: An early experience
Authors: B. Moran
Company
Brachytherapy
Theranostics
Company
©2023. All rights reserved. Terms & Privacy | Privacy Policy